Infinimmune and Merck Enter Antibody Discovery Agreement
Infinimmune has entered into an antibody discovery agreement with Merck (MRK), which includes potential milestone payments of $838 million and an undisclosed upfront payment. The collaboration involves using Infinimmune's technology to discover and improve naturally existing antibodies with AI methods for Merck's selected targets. The deal grants Merck exclusive rights to develop and commercialize the resulting medicines.
Tickers: $MRK
Topics: AI in drug development antibody discovery biotech partnerships pharmaceutical research